SecBot SecBot
SECBOTREPLAY Home › Report › RYTM

RYTM · Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M…

Rhythm Pharmaceuticals, Inc. · PRESS-RELEASE filed Aug 4, 2026 at 07:01 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Aug 4, 2026 at 07:01 ET

Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.73 (vs -$0.83 consensus, a 12.0% beat), driven by a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). The company also announced positive preliminary Phase 2 data for its weekly injectable MC4R agonist RM-718, showing an -11.6% mean BMI reduction at 16 weeks, and narrowed its 2026 Non-GAAP OpEx guidance to $363M-$397M (from $385M-$415M). The combination of a top- and bottom-line beat, accelerating U.S. revenue growth (+38% QoQ), and encouraging pipeline data is a clear positive signal for the commercial story and long-term growth trajectory.

  • Q2 2026 revenue $71.3M vs consensus $67.7M (+5.3% beat)
  • GAAP EPS -$0.73 vs consensus -$0.83 (+12.0% beat)
  • U.S. IMCIVREE revenue $51.0M, up 38% QoQ from Q1 2026
  • Over 400 patient start forms for IMCIVREE in acquired HO since FDA approval

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access